APA (7th ed.) Citation

PY, L., BS, Z., JJ, C., BY, Z., MW, S., CM, H., . . . CS, L. (2026). Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: A network meta-analysis of 270,471 participants. Journal of hematology & oncology, 19(1), . https://doi.org/10.1186/s13045-026-01788-5

Chicago Style (17th ed.) Citation

PY, Lin, et al. "Agent-specific, Histopathology-stratified Hematologic Malignancy Risk Among Dpp-4 Inhibitors, Glp-1 Receptor Agonists, and SGLT2 Inhibitors: A Network Meta-analysis of 270,471 Participants." Journal of Hematology & Oncology 19, no. 1 (2026). https://doi.org/10.1186/s13045-026-01788-5.

MLA (9th ed.) Citation

PY, Lin, et al. "Agent-specific, Histopathology-stratified Hematologic Malignancy Risk Among Dpp-4 Inhibitors, Glp-1 Receptor Agonists, and SGLT2 Inhibitors: A Network Meta-analysis of 270,471 Participants." Journal of Hematology & Oncology, vol. 19, no. 1, 2026, https://doi.org/10.1186/s13045-026-01788-5.